Insights into the Evolving Disease and Treatment Landscape of Lower-Risk MDS

Experts review best practices for identifying and diagnosing patients with lower-risk MDS.

Drs Safah and Koprivnikar review updates made to the WHO and ICC guidelines when classifying MDS as well as discussing the impact of molecular alterations when treating MDS.

Hana Safah, MD explains how the risk stratification for MDS has evolved over time and provides an in-depth of the current risk stratification tools, IPSS, IPSS-R and IPSS-M.

Clinicians discuss the importance of early detection in patients with MDS as well as providing insights into some of the unmet needs in MDS, such as a better understanding of the role of molecular alterations and its specific impact in MDS.

Insights into treatment goals and review of the current treatment landscape for lower-risk MDS.

Experts comment on factors that influence their decision-making when treating patients with lower-risk MDS.

Dr Hana Safah discusses the role of stem cell transplant and reviews the eligibility criteria.

Clinicians review the MEDALIST trial, which evaluated luspatercept in the second-line setting and comment on updated data from MEDALIST that was recently presented at the annual ASH 2023 meeting.

Drs Safah and Koprivinikar discuss emerging therapies, such as imetelstat and canakinumab, and where they might fit in the treatment paradigm for lower-risk MDS.